Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demon...
Guardado en:
Autores principales: | Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Beyond Trinucleotide Repeat Expansion in Fragile X Syndrome: Rare Coding and Noncoding Variants in <i>FMR1</i> and Associated Phenotypes
por: Cedrik Tekendo-Ngongang, et al.
Publicado: (2021) -
Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions
por: Snow Bach, et al.
Publicado: (2021) -
Búsqueda de afecciones genéticas como etiología de déficit intelectual en individuos que asisten a escuelas de educación especial
por: Alliende,M Angélica, et al.
Publicado: (2008) -
Conceptual Perspectives on State Fragility
por: D. P. Elagin
Publicado: (2021) -
Fragile X Syndrome and Targeted Treatments
por: Nattaporn Tassanakijpanich, et al.
Publicado: (2020)